Cardiac biomarkers are proteins that are released into the blood when the heart muscle is stressed. They play a vital role in the diagnosis and management of acute coronary syndromes and myocardial infarction. Common cardiac biomarkers include troponin, CK-MB, myoglobin, BNP, and others. The cardiac biomarkers market has witnessed significant growth in recent times due to the increasing prevalence of cardiovascular diseases and growing adoption of point-of-care testing. Point-of-care testing delivers test results quicker and allows for fast clinical decision making. It is widely adopted in hospitals, diagnostic laboratories, and other healthcare settings for rapid diagnosis of heart attacks.
The global cardiac biomarkers market is estimated to be valued at US$ 9836.55 in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics: One of the key drivers for the growth of the cardiac biomarkers market is the increasing adoption of point-of-care testing. Point-of-care testing offers immediate diagnosis of cardiovascular conditions without the need for centralized laboratories. It provides test results in less than 30 minutes compared to several hours taken by other conventional laboratory methods. This enables critical clinical decision making and early intervention. Moreover, it is convenient for patients as it does away with transportation time to a diagnostic laboratory. Faster diagnostic information with point-of-care testing helps in improving patient outcomes in acute care settings.
Segment Analysis
The global Cardiac Biomarkers market is dominated by the diagnostic segment which holds more than 85% share. Within diagnostics, the cardiac troponins (cTn) sub-segment leads with over 70% share owing to their high sensitivity and cardiac specificity. The cTn biomarkers help in early detection of myocardial injury and have replaced myoglobin and CK-MB for diagnosing myocardial infarction as per the new guidelines.
PEST Analysis
Political: The market is favourbale impacted by initiatives taken by various governments and regulatory bodies to spread awareness about heart diseases and enhance diagnostics.
Economic: Rising geriatric population and increasing healthcare spending on cardiology indicate long term groth prospects for biomarkers.
Social: Growing burden of cardiac conditions and rising demand for minimally invasive testing is driving increased adoption of biomarkers.
Technological: Advancements in assay sensitivity have enabled earlier detection of myocardial injury. Miniaturization of platforms aid point-of-care testing.
Key Takeaways
The Global Cardiac Biomarkers Market Share is expected to witness high growth at a CAGR of 6.0% during the forecast period of 2023 to 2030.
Regionally, North America dominated with over 40% market share in 2024 led by US on back of advanced healthcare facilities and high diagnostic rate for cardiac diseases. Asia Pacific is expected to be the fastest growing region due to rising awareness, healthcare investments and growing disease prevalence in countries like China and India.
Key players operating in the cardiac biomarkers market are Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Randox Laboratories Ltd., Siemens Healthineers, and BioMérieux SA. Abbott holds the largest share owing to its robust product portfolio of analyzer systems and reagents for high, mid and low throughput settings. Roche and Siemens are other major players focusing on assays for myoglobin, CK-MB and high sensitivity and specificity troponin tests.
For more details on the report, Read- https://www.pressreleasebulletin.com/cardiac-biomarkers-market-trends-size-and-share-analysis/
Explore more trending article on this topic: https://www.shayaricenter.com/natures-barcodes-biomarkers-illuminate-paths-to-wellness-and-scientific-breakthroughs
